<DOC>
	<DOCNO>NCT00253474</DOCNO>
	<brief_summary>RATIONALE : PEG-interferon alfa-2b may interfere growth tumor cell . PURPOSE : This phase I trial study side effect best dose PEG-interferon alfa-2b treat young patient plexiform neurofibroma .</brief_summary>
	<brief_title>PEG-Interferon Alfa-2b Treating Young Patients With Plexiform Neurofibroma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose PEG-interferon alfa-2b patient unresectable plexiform neurofibroma . ( Dose escalation portion study close accrual 2/2005 . ) - Determine toxicity profile drug patient . Secondary - Obtain , preliminary , information efficacy drug patient . - Evaluate growth rate plexiform neurofibroma use volumetric MRI analysis patient treat drug . - Evaluate impact drug , term `` bad symptom '' score , patient . OUTLINE : This dose-escalation , multicenter study . ( Dose-escalation portion study close accrual 2/2005 . ) Patients receive PEG-interferon alfa-2b subcutaneously weekly 2 year absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos PEG-interferon alfa-2b maximum tolerate dose ( MTD ) determine . The MTD define dose precede 1 6 patient experience dose-limiting toxicity . A total 12 patient receive treatment MTD . After completion study treatment , patient follow every 6 month . PROJECTED ACCRUAL : A total 36 patient accrue study .</detailed_description>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Neurofibromatoses</mesh_term>
	<mesh_term>Nerve Sheath Neoplasms</mesh_term>
	<mesh_term>Neurofibroma , Plexiform</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis plexiform neurofibroma progressive , symptomatic , life threaten standard medical management surgical option Histologic confirmation tumor require presence consistent clinical radiographic finding provide follow true : No clinical observation scan suggestive malignant transformation Meets ≥ 1 follow diagnostic criterion neurofibroma type 1 ( NF1 ) : Six cafeaulait spot ( &gt; 0.5 cm prepubertal patient &gt; 1.5 cm post pubertal patient ) Freckling axilla groin Optic glioma Two Lisch nodule A distinctive bony lesion ( e.g. , dysplasia sphenoid bone , dysplasia , thin long bone cortex ) A first degree relative NF1 No history malignant peripheral nerve sheath tumor No active visual pathway glioma No active brain tumor brain metastasis PATIENT CHARACTERISTICS : Performance status ECOG 02 Life expectancy At least 12 month Hematopoietic Absolute neutrophil count &gt; 1,500/mm^3 Hemoglobin &gt; 10 g/dL Platelet count &gt; 100,000/mm^3 Hepatic Bilirubin &lt; 1.5 mg/dL SGPT ≤ 2 time upper limit normal No significant hepatic dysfunction Renal Creatinine base age follow : ≤ 0.8 mg/dL ( patient age 5 year ) ≤ 1.0 mg/dL ( patient age 6 10 year ) ≤ 1.2 mg/dL ( patient age 11 15 year ) ≤ 1.5 mg/dL ( patient age 16 21 year ) OR Creatinine clearance ≥ 70 mL/min Cardiovascular No significant cardiac dysfunction No severe cardiovascular disease No cardiac arrhythmia require chronic treatment No congestive heart failure No symptomatic ischemic heart disease Pulmonary No significant pulmonary dysfunction Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious infection No significant unrelated systemic illness No significant organ dysfunction No malignancy except surgically cure nonmelanoma skin cancer carcinoma situ cervix No history severe psychiatric condition psychiatric disorder require hospitalization No history suicidal ideation attempt No thyroid dysfunction unresponsive therapy No uncontrolled diabetes mellitus No history HIV positivity No alcohol drug abuse PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy No concurrent colonystimulating factor ( e.g. , erythropoietin filgrastim [ GCSF ] ) Chemotherapy No concurrent chemotherapy disease Endocrine therapy No concurrent chronic systemic corticosteroid No concurrent hormonal therapy disease Radiotherapy No concurrent radiotherapy disease Surgery Prior surgery allow provide least 21 day since surgery presence residual tumor Other Recovered prior therapy More 30 day since prior investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>neoplasm uncertain malignant potential</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>